Article
The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
Pharmacogenetics - 1 Jan 2004
Visser Loes E, van Vliet Martin, van Schaik Ron H N, Kasbergen A A Harrie, De Smet Peter A G M, Vulto Arnold G, Hofman Albert, van Duijn Cornelia M, Stricker Bruno H Ch
Abstract excerpt
Cytochrome P4502C9 (CYP2C9) is the main enzyme implicated in coumarin anticoagulant metabolism. The variant alleles CYP2C9*2 and CYP2C9*3 are associated with an increased response to warfarin. However, an effect on acenocoumarol dose requirements appears to be absent for the CYP2C9*2 allele and the consequences for the metabolism of phenprocoumon have not yet been established. We investigated CYP2C9 polymorphisms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.